World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 1 April 2019
Main ID:  NCT03528551
Date of registration: 18/04/2018
Prospective Registration: Yes
Primary sponsor: Novo Nordisk A/S
Public title: A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A pathfinder8
Scientific title: Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia A
Date of first enrolment: April 30, 2018
Target sample size: 173
Recruitment status: Enrolling by invitation
Study type:  Interventional
Study design:  Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 3
Countries of recruitment
Australia Brazil Canada Croatia Denmark France Germany Greece
Hungary Israel Italy Japan Korea, Republic of Lithuania Malaysia Netherlands
Norway Portugal Puerto Rico Spain Switzerland Taiwan Turkey Ukraine
United Kingdom United States
Name:     Clinical Reporting Anchor and Disclosure 1452
Affiliation:  Novo Nordisk A/S
Key inclusion & exclusion criteria

Inclusion Criteria:

- Male patients of all ages with the diagnosis of severe congenital haemophilia A
(coagulation Factor VIII [FVIII] activity less than 1%) based on medical records

- On-going participation in NN7088-3859 (pathfinder2), or NN7088-3885 (pathfinder5) at
the time of transfer

Exclusion Criteria:

- Known or suspected hypersensitivity to trial product including allergy to hamster
protein or related products

- Any disorder, except for conditions associated with haemophilia, which in the
investigator's opinion might jeopardise patient's safety or compliance with the
protocol - Current participation in any clinical trial (except NN7088-3859
(pathfinder2) or NN7088-3885 (pathfinder5)) of an approved or non-approved
investigational medicinal product

Age minimum: N/A
Age maximum: N/A
Gender: Male
Health Condition(s) or Problem(s) studied
Congenital Bleeding Disorder
Haemophilia A
Drug: Turoctocog alfa pegol
Primary Outcome(s)
Number of adverse events reported [Time Frame: Weeks 0-104]
Secondary Outcome(s)
Change from start till end of trial in treatment satisfaction (based on Hemo-SAT score) [Time Frame: Week 0, Week 104]
Change in joint health status from start to end of trial (based on Haemophilia Joint Health Score) [Time Frame: Week 0, Week 104]
Consumption of N8-GP during prophylaxis treatment [Time Frame: Weeks 0-104]
Consumption of N8-GP per bleed [Time Frame: Weeks 0-104]
Haemostatic effect of N8-GP when used for treatment of bleeding episodes assessed as: Excellent, Good, Moderate, or None [Time Frame: Weeks 0-104]
Haemostatic response during major surgical interventions assessed as: Excellent, Good, Moderate, or None [Time Frame: Weeks 0-104]
Incidence of FVIII inhibitors =0.6 BU [Time Frame: Weeks 0-104]
Number of bleeding episodes on prophylaxis [Time Frame: Weeks 0-104]
Number of N8-GP injections required per bleeding episode [Time Frame: Weeks 0-104]
Number of spontaneous bleeding episodes on prophylaxis [Time Frame: Weeks 0-104]
Pre-dose FVIII activity levels on N8-GP prophylaxis (IU/dL) [Time Frame: Weeks 0-104]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history